TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21375745

Group type: EXPERIMENTAL
Intervention: Coiling
Number of subjects: 80

Group type: COMPARATOR
Intervention: Conservative management
Number of subjects: 80
Study: 19368581

Group type: EXPERIMENTAL
Intervention: Acellular matrix (AM)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Standard of care (control)
Number of subjects: 86
Study: 17823448

Group type: EXPERIMENTAL
Intervention: 4 g/d of 78% active CLA isomers (3.2 g/d: 39.2% cis‐9,trans‐11 and 38.5% trans‐10,cis‐12)
Number of subjects: 23

Group type: COMPARATOR
Intervention: 4 g/d of safflower oil (placebo)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: 4 g/d of 78% active CLA isomers
Number of subjects: 23
Study: 15044507

Group type: EXPERIMENTAL
Intervention: Responders (medicated with cyclosporin)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Controls (non-medicated subjects)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Non-responders (without gingival overgrowth)
Number of subjects: 3
Study: 12232756

Group type: EXPERIMENTAL
Intervention: full‐PCT
Number of subjects: 261

Group type: COMPARATOR
Intervention: telephone‐PCT
Number of subjects: 261
Study: 10709412

Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Class I antiarrhythmic drugs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Class III drugs (sotalol and amiodarone)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: D-sotalol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Implantable cardioverter-defibrillator (ICD) therapy
Number of subjects: 0
Study: 7668214

Group type: EXPERIMENTAL
Intervention: Hirulog
Number of subjects: 4312

Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 4312
Study: 2183505

Group type: EXPERIMENTAL
Intervention: Systemic treatment with cyclosporin A (CSA) at a dosage of 2.5 mg/kg/d for 10 weeks
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Topical application of cyclosporin A (CSA) in 1/5/10% gel and ointment
Number of subjects: 53
Study: 6778754

Group type: EXPERIMENTAL
Intervention: Nitroglycerin ointment (15 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 6149511

Group type: EXPERIMENTAL
Intervention: Timolol
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Metipranol
Number of subjects: 100
Study: 31079328

Group type: COMPARATOR
Intervention: 0.0 mg of chromium picolinate (CrPic) supplementation per ewe (T1)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 0.15 mg of CrPic per ewe (T2)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 0.30 mg of CrPic per ewe (T3)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 0.45 mg of CrPic per ewe (T4)
Number of subjects: 32
Study: 29803838

Group type: EXPERIMENTAL
Intervention: Over-the-scope clips (OTSC)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Standard therapy (through-the-scope clips and thermal therapy plus injection with diluted adrenaline)
Number of subjects: 66
Study: 26628445

Group type: EXPERIMENTAL
Intervention: Intensive, manual-based behavioral feeding intervention for children with chronic food refusal
Number of subjects: 20

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 20
Study: 24961331

Group type: EXPERIMENTAL
Intervention: Graduated compression bandage with pressure of 20-40 mm Hg
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional compression bandage with pressure of 10-20 mm Hg
Number of subjects: 100
Study: 22288931

Group type: EXPERIMENTAL
Intervention: Portex stylet
Number of subjects: 60

Group type: COMPARATOR
Intervention: Portex single-use bougie
Number of subjects: 60

Group type: COMPARATOR
Intervention: Frova single-use bougie
Number of subjects: 60

Group type: COMPARATOR
Intervention: Portex reusable bougie
Number of subjects: 60
Study: 20483153

Group type: EXPERIMENTAL
Intervention: Electronic medical record scribe
Number of subjects: 5

Group type: COMPARATOR
Intervention: No scribe (Control)
Number of subjects: 5
Study: 17919651

Group type: EXPERIMENTAL
Intervention: Facilitative problems group
Number of subjects: 35

Group type: COMPARATOR
Intervention: Nonfacilitative problems group
Number of subjects: 35
Study: 15707560

Group type: EXPERIMENTAL
Intervention: 20 microg ethinyl estradiol combined with 100 microg levonorgestrel (20 EE/100 LNG)
Number of subjects: 48

Group type: COMPARATOR
Intervention: 30 microg ethinyl estradiol combined with 150 microg levonorgestrel (30 EE/150 LNG)
Number of subjects: 48
Study: 12844088

Group type: EXPERIMENTAL
Intervention: Guidant/EVT bifurcated endograft
Number of subjects: 573

Group type: COMPARATOR
Intervention: Open repair
Number of subjects: 573
Study: 10228290

Group type: EXPERIMENTAL
Intervention: Intermittent left vagal nerve stimulation
Number of subjects: 60
Study: 8960733

Group type: EXPERIMENTAL
Intervention: Liquid levodopa/carbidopa (LD/CD)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Tablet levodopa/carbidopa (LD/CD)
Number of subjects: 23
Study: 1662376

Group type: EXPERIMENTAL
Intervention: Monoclonal anti-CD3 antibody
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Anti-thymocyte globulins
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: HLA DR compatibility
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: HLA B + DR compatibility
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: DR incompatibilities
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Symptoms and severity of CMV infection
Number of subjects: 143

Group type: COMPARATOR
Intervention: Graft rejection
Number of subjects: 143
Study: 7049955

Group type: EXPERIMENTAL
Intervention: Antimicrobial decontamination based on sensitivity tests
Number of subjects: 35

Group type: COMPARATOR
Intervention: Standard combination of neomycin, cephaloridin, polymyxin B or E and nystatin or amphotericin B
Number of subjects: 35
Study: 30724002

Group type: COMPARATOR
Intervention: Licogliflozin 150 mg q.d. for 12 weeks
Number of subjects: 88

Group type: COMPARATOR
Intervention: Licogliflozin 300 mg single dose prior to OGTT
Number of subjects: 88

Group type: COMPARATOR
Intervention: Licogliflozin 15 mg q.d. for 14 days
Number of subjects: 88
Study: 29871676

Group type: EXPERIMENTAL
Intervention: Care by patient navigators based on standardized operating procedures
Number of subjects: 340

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: Patient-related outcomes measured using questionnaires (SF 36, HADS, PAM 13, and others)
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: Data on drug therapy, utilization of health services, and medical expenses
Number of subjects: 340
Study: 27100457

Group type: EXPERIMENTAL
Intervention: Functional Movement-Power Training (FMPT)
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Functional Movement Training (FMT)
Number of subjects: 161

Group type: COMPARATOR
Intervention: Control
Number of subjects: 161
Study: 25985582

Group type: EXPERIMENTAL
Intervention: Letosteine (50mg thrice daily)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Ambroxol hydrochloride (30mg thrice daily)
Number of subjects: 240
Study: 22053748

Group type: EXPERIMENTAL
Intervention: Proximity-based hazard (PBH) modeling with varying attributes of hazard value, proximity, prevalence, and dot patterns.
Number of subjects: 447

Group type: EXPERIMENTAL
Intervention: Hazard value, location in or out of a clustered dot pattern, and distance.
Number of subjects: 447

Group type: EXPERIMENTAL
Intervention: Interaction of hazard value with other attributes.
Number of subjects: 447

Group type: EXPERIMENTAL
Intervention: Combined maps of PBH and attributes.
Number of subjects: 447
Study: 18559130

Group type: EXPERIMENTAL
Intervention: Community-based nutrition and growth promotion intervention provided by the Senegal Nutrition Enhancement Project
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (villages not receiving the intervention)
Number of subjects: 0
Study: 17145784

Group type: EXPERIMENTAL
Intervention: Ofloxacin (20 mg/kg/day for 7 days)
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Ofloxacin-Azithromycin (15 mg/kg/day of ofloxacin for 7 days and 10 mg/kg/day of azithromycin for the first 3 days)
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Azithromycin (10 mg/kg/day for 7 days)
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Ofloxacin-Azithromycin
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Ofloxacin
Number of subjects: 187
Study: 15807195

Group type: EXPERIMENTAL
Intervention: Statins (HMG-CoA reductase inhibitors)
Number of subjects: 0
Study: 12113133

Group type: EXPERIMENTAL
Intervention: Eradication of Helicobacter pylori
Number of subjects: 0

Group type: COMPARATOR
Intervention: Surgical intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Irradiation and chemotherapy
Number of subjects: 0
Study: 9481021

Group type: EXPERIMENTAL
Intervention: CD-ROM program
Number of subjects: 24

Group type: COMPARATOR
Intervention: Reading control group
Number of subjects: 24
Study: 8056571

Group type: EXPERIMENTAL
Intervention: Assertiveness Training (AT)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Alternate Treatment Control (ATC)
Number of subjects: 60
Study: 2468913

Group type: EXPERIMENTAL
Intervention: Verapamil (VER, 240 mg/day)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Nifedipine (NIF, 40 mg/day)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 31726072

Group type: EXPERIMENTAL
Intervention: Embotrap added to contact aspiration (CA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Contact aspiration (CA) alone
Number of subjects: 0
Study: 31272379

Group type: EXPERIMENTAL
Intervention: LMA-Protector™
Number of subjects: 110

Group type: COMPARATOR
Intervention: i-gel™
Number of subjects: 110
Study: 28009794

Group type: EXPERIMENTAL
Intervention: Proclear Multifocal (Distance/Near)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: ACUVUE Oasys for Presbyopia
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Air Optix Aqua Multifocal
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control (dilated pupil without contact lens)
Number of subjects: 16
Study: 25853591

Group type: EXPERIMENTAL
Intervention: Citrate and calcium
Number of subjects: 212

Group type: COMPARATOR
Intervention: Heparin and protamine
Number of subjects: 212
Study: 24047844

Group type: EXPERIMENTAL
Intervention: Papacarie Duo™
Number of subjects: 20

Group type: COMPARATOR
Intervention: Low-speed bur
Number of subjects: 20
Study: 21070775

Group type: EXPERIMENTAL
Intervention: Peginterferon and ribavirin therapy
Number of subjects: 341
Study: 19269299

Group type: EXPERIMENTAL
Intervention: High-intensity strawberry lemonade (group Strong; n=20)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Low-intensity strawberry lemonade (group Weak; n=20)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Lemonade that increased in flavour intensity (group Increase; n=20)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Lemonade that decreased in flavour intensity (group Decrease; n=20)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Lemonade that retained a given intensity (group Same; n=20)
Number of subjects: 100
Study: 16544443

Group type: EXPERIMENTAL
Intervention: Intragastric balloons
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Weight-reduction program adherence
Number of subjects: 0
Study: 15531766

Group type: EXPERIMENTAL
Intervention: abciximab
Number of subjects: 701

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 701
Study: 11230065

Group type: EXPERIMENTAL
Intervention: Involvement of consumers in clinical trial coordinating centres
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Input from consumers in 48 individual trials
Number of subjects: 62
Study: 9242972

Group type: EXPERIMENTAL
Intervention: Cafestol (61-64 mg/day)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Cafestol (60 mg/day) and kahweol (48-54 mg/day)
Number of subjects: 10
Study: 8270716

Group type: EXPERIMENTAL
Intervention: Protected telescoping catheter (PTC‐NB)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Protected telescoping catheter (PTC‐B)
Number of subjects: 40

Group type: COMPARATOR
Intervention: PTC‐NB and PTC‐B
Number of subjects: 40

Group type: COMPARATOR
Intervention: PTC‐B
Number of subjects: 40
Study: 3535433

Group type: EXPERIMENTAL
Intervention: Nova-T
Number of subjects: 1243

Group type: COMPARATOR
Intervention: MLCu375
Number of subjects: 1243
Study: 31830094

Group type: EXPERIMENTAL
Intervention: Real tDCS
Number of subjects: 13

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 13
Study: 28983994

Group type: EXPERIMENTAL
Intervention: HIT+β2 A (daily inhalation of β2 ‐agonist terbutaline, 4 mg dose-1)
Number of subjects: 21

Group type: COMPARATOR
Intervention: HIT (high intensity training without β2 ‐agonist)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: HIT+β2 A
Number of subjects: 21

Group type: COMPARATOR
Intervention: HIT
Number of subjects: 21
Study: 26022118

Group type: EXPERIMENTAL
Intervention: 0.2% Chlorhexidine mouthwash (M-0.2% CHX)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 0.2% Chlorhexidine mouthwash followed by tooth-brushing and 1% acetic acid (M-0.2% CHX+NP)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Sterile water mouthwash (M-WATER)
Number of subjects: 15
Study: 24326928

Group type: EXPERIMENTAL
Intervention: Respiratory muscle endurance training (RMET)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (no RMET)
Number of subjects: 12
Study: 22621750

Group type: EXPERIMENTAL
Intervention: Short-term adjunctive subantimicrobial dose doxycycline (SDD)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 19546674

Group type: EXPERIMENTAL
Intervention: 1.5 mL 0.25% bupivacaine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 40
Study: 17697223

Group type: EXPERIMENTAL
Intervention: TruView EVO2 laryngoscope
Number of subjects: 200

Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 200
Study: 15336473

Group type: EXPERIMENTAL
Intervention: Combined typhoid fever/HAV vaccine (3 batches)
Number of subjects: 610
Study: 12575377

Group type: EXPERIMENTAL
Intervention: Shenqi tablet (SQT)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 63
Study: 8021539

Group type: EXPERIMENTAL
Intervention: Teflon cannula with a 26-gauge introducer needle and a 24-gauge cannula
Number of subjects: 20

Group type: COMPARATOR
Intervention: 25-gauge butterfly needle
Number of subjects: 20
Study: 2723122

Group type: EXPERIMENTAL
Intervention: Slow-release potassium citrate tablets (60 meq)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Rapid-release liquid potassium citrate preparation (60 meq)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 4888876

Group type: EXPERIMENTAL
Intervention: Propranolol 30 mg twice daily
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control (Digitalis only)
Number of subjects: 6
Study: 31286883

Group type: EXPERIMENTAL
Intervention: Supreme Laryngeal Mask Airway (SLMA)
Number of subjects: 920

Group type: COMPARATOR
Intervention: Endotracheal Intubation (ETT)
Number of subjects: 920
Study: 28408655

Group type: EXPERIMENTAL
Intervention: Leaded ammunition
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Unleaded ammunition
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Modified unleaded ammunition
Number of subjects: 54
Study: 25427171

Group type: EXPERIMENTAL
Intervention: Zonisamide (400 mg/d)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Topiramate (300 mg/d)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Levetiracetam (2000 mg/d)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 24278992

Group type: EXPERIMENTAL
Intervention: tenofovir/emtricitabine/raltegravir (Switch Group)
Number of subjects: 30

Group type: COMPARATOR
Intervention: tenofovir/emtricitabine/efavirenz (Continuation Group)
Number of subjects: 30
Study: 21666939

Group type: EXPERIMENTAL
Intervention: Alpha-lipoic acid (ALA) 300 mg daily
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study: 19948518

Group type: EXPERIMENTAL
Intervention: Dexamethasone (1 mg/kg at induction of anesthesia and 0.5 mg/kg 8 hours later)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 100
Study: 17015551

Group type: EXPERIMENTAL
Intervention: Dexamethasone (n = 38)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo (n = 30)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 68
Study: 12711645

Group type: EXPERIMENTAL
Intervention: Routine planning protocol used by each department
Number of subjects: 56

Group type: COMPARATOR
Intervention: Larger breast size distributions
Number of subjects: 56

Group type: COMPARATOR
Intervention: Two-dimensional contour planning
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Plan optimization by selecting appropriate beam parameters
Number of subjects: 56
Study: 10576671

Group type: EXPERIMENTAL
Intervention: Road trauma film
Number of subjects: 109

Group type: COMPARATOR
Intervention: Neutral film
Number of subjects: 109
Study: 9145958

Group type: EXPERIMENTAL
Intervention: Glycolic acid peels (68% maximum concentration) in addition to 2% hydroquinone/10% glycolic acid gel twice daily and 0.05% tretinoin cream at night.
Number of subjects: 19

Group type: COMPARATOR
Intervention: 2% hydroquinone/10% glycolic acid gel twice daily and 0.05% tretinoin cream at night (control group).
Number of subjects: 19
Study: 7942577

Group type: EXPERIMENTAL
Intervention: Human milk
Number of subjects: 59

Group type: COMPARATOR
Intervention: Standard term formula, standard preterm formula, experimental preterm formula
Number of subjects: 59

Group type: COMPARATOR
Intervention: Formula feeding (all types)
Number of subjects: 59

Group type: COMPARATOR
Intervention: All feeding groups
Number of subjects: 59
Study: 3144300

Group type: EXPERIMENTAL
Intervention: Diazepam 10 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Chlormethiazole 250 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Chlormethiazole 500 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 29605787

Group type: EXPERIMENTAL
Intervention: Blended training (self-training video, website, Moodle platform, intelligent manikin, 45 min instructor presence)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Control group (face-to-face training based on ERC Guidelines)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Blended training
Number of subjects: 129

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 129
Study: 26685850

Group type: COMPARATOR
Intervention: ProTaper® rotary system
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Reciproc® system
Number of subjects: 78
Study: 25604900

Group type: EXPERIMENTAL
Intervention: 50 mg/day DHEA
Number of subjects: 99

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study: 24326568

Group type: EXPERIMENTAL
Intervention: Bimatoprost 0.03% solution, applied once daily to the upper eyelid margin for 6 months
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bimatoprost 0.03% solution
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (vehicle control)
Number of subjects: 0
Study: 22137073

Group type: EXPERIMENTAL
Intervention: Supervised exercise training plus usual care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 0
Study: 18077316

Group type: EXPERIMENTAL
Intervention: E(2)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: E(2) + MPA
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Tibolone
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: All hormonal treatments (E(2), E(2) + MPA, Tibolone)
Number of subjects: 30
Study: 16518347

Group type: EXPERIMENTAL
Intervention: BNP (4 pmol/kg/min)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: BNP with ET-B receptor antagonist BQ-788 (50 nmol/min)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (i.v.)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: BQ-788 infusion
Number of subjects: 10
Study: 14512076

Group type: EXPERIMENTAL
Intervention: American university students' drinking patterns pamphlet
Number of subjects: 0

Group type: COMPARATOR
Intervention: Canadian population drinking patterns pamphlet
Number of subjects: 0

Group type: COMPARATOR
Intervention: Canadian university students' drinking patterns pamphlet
Number of subjects: 0
Study: 11053723

Group type: EXPERIMENTAL
Intervention: 8-mm tip electrode catheter
Number of subjects: 0

Group type: COMPARATOR
Intervention: 4-mm tip electrode catheter
Number of subjects: 0
Study: 9177879

Group type: EXPERIMENTAL
Intervention: Neutrophils from patients with burns stimulated with FMLP
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Neutrophils from patients with burns stimulated with (Ser‐IL‐8)77
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Neutrophils from patients with burns stimulated with (Ala‐IL‐8)77
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Neutrophils from patients with burns stimulated with Fc gamma RII crosslinking
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Neutrophils from patients with burns after stimulation with FMLP
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Neutrophils from patients with burns after stimulation with C5a
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Neutrophils from patients with burns after stimulation with (Ser‐IL‐8)72
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Neutrophils from patients with burns after stimulation with Fc gamma RII crosslinking
Number of subjects: 11

Group type: COMPARATOR
Intervention: Neutrophils from patients with burns at discharge
Number of subjects: 11
Study: 8358135

Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: 2% lignocaine
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control blocks (not specified)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Single diagnostic blocks
Number of subjects: 55
Study: 3324800

Group type: EXPERIMENTAL
Intervention: Naloxone treatment
Number of subjects: 19

Group type: COMPARATOR
Intervention: Saline treatment
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Ethanol intoxication (CPAF group)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Ethanol intoxication (nonflushing group)
Number of subjects: 19